The government has signalled a shift in India’s pharmaceutical research strategy toward industry-linked and market-oriented innovation, following a review of activities at NIPER Mohali.
The institute showcased ongoing work in cell and gene therapies, biosimilars, and AI-driven pharmacoinformatics (drug research), alongside collaborations with industry and clinical research initiatives. These areas are aligned with the broader Biopharma SHAKTI mission, which aims to build domestic capacity in high-value pharmaceutical segments.
A critical theme of the visit was the acceleration of translational research, with the need to move from “paper patents” to commercial products, with greater emphasis on technology transfer and industry-funded research. This includes incentivising faculty to secure external funding and strengthening institutional linkages with private firms.
To support this shift, NIPER Mohali has introduced new Master’s programmes in Biopharmaceuticals and Regulatory Affairs, aimed at building a workforce suited to global industry requirements.
Key Statistical and Innovation Benchmarks
Inauguration: Launch of the Medicinal Succulents Garden for research.
Research Focus: Advancement in APIs, key starting materials, and biologics.
Emerging Tech: Development of cell and gene therapies and medical devices.
Academic Expansion: Introduction of specialized Master's programmes.
Policy Directive: Call for transition from patents to commercial technology transfer.
Governance: Emphasis on increasing industry-sponsored research.
What is "Translational Research" in Pharma?
Translational research is the process of turning basic scientific discoveries made in a laboratory into practical applications, such as new drugs, medical devices, or treatment protocols. In the context of NIPER Mohali, the government is pushing to ensure that pharmaceutical research does not just result in a "paper patent" (a patent that exists only as a document), but actually moves through clinical trials and industry partnerships to become a product available in the market. This "bench-to-bedside" approach is essential for building a self-reliant biopharmaceutical ecosystem that directly improves public health and drives economic growth.
Policy Relevance
Secures API Supply Chain: Prioritising research into Active Pharmaceutical Ingredients (APIs) and key starting materials reduces India's dependence on foreign imports for basic drug manufacturing.
Drives Innovation-Led Growth: Shifting faculty incentives toward external funding and industry-sponsored research aligns academic output with market demands.
Modernizes Regulatory Frameworks: New programmes in Regulatory Affairs ensure that the workforce is equipped to handle complex global compliance standards for biosimilars and medical devices.
Leverages AI in Healthcare: Utilising pharmacoinformatics and AI-driven drug delivery positions India at the cutting edge of global pharmaceutical technology.
Promotes Industry-Academia Synergy: The Biopharma SHAKTI mission serves as a bridge, ensuring that high-end research at institutions like NIPER is directly commercialised by the Indian pharmaceutical industry.
Relevant Question for Policy Stakeholders: With the push for transitioning from 'paper patents' to real-world commercialization, what specific institutional mechanisms can NIPER Mohali implement to facilitate faster technology transfer to MSMEs in the Indian biopharma sector?
Follow the Full News Here: Union Minister Shri J. P. Nadda Visits NIPER Mohali